A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Latest Information Update: 20 Jun 2024
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma America
- 17 Jun 2024 According to a Mitsubishi Tanabe Pharma America media release, results from this study presented at the European Network for a Cure for ALS (ENCALS) 2024 meeting taking place in Stockholm, Sweden.
- 17 Jun 2024 Results published in the Mitsubishi Tanabe Pharma America media release Media Release
- 05 Jun 2024 According to a Mitsubishi Tanabe Pharma America media release, final data presentation from this trial to be included in a presentation at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 Annual Meeting being held in Stockholm, Sweden from June 17-20, 2024.